Bassett, A.R., Tibbit, C., Ponting, C.P., Liu, J.L. (2023). Highly efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9 system. Cell Reports. 4 (1), 220–228.
Bigdeli, A. (2020). Hybrid Intelligence. Scientific Journal of Research Approaches in the Social Sciences, 6(1), 61-74. [In Persian]
Bouabe, H., Okkenhaug, K. (2023). Gene targeting in mice: a review. Methods Mol Biol. 1064:315–36.
Capecchi, M.R. (2025). Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat Rev Genet. 6(6),507–12.
Cho, S.W., Kim, S., Kim, Y., Kweon, J., Kim, H.S., Bae, S., et al. (2024) Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Resarche. 24 (1), 132–41.
Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., et al. (2023). Multiplex genome engineering using CRISPR/Cas systems. Science. 339(6121):819–23.
Cox, D.B., Platt, R.J., Zhang, F. (2015). Therapeutic genome editing: prospects and challenges. Nat Med, 21 (2),121–31.
Fatollahi Arani, S., Zeinoddini, M. (2023). Gene editing: biosecurity challenges and risks. J Police Med.12(1), 1-19. [In Persian]
Ferry, Q.R., Lyutova, R., Fulga, T.A. (2017). Rational design of inducible CRISPR guide RNAs for de novo assembly of transcriptional programs. Nat Commun, 8: 14633.
Finer, M., Glorioso, J. (2017). a brief account of viral vectors and their promise for gene therapy. Gene Ther, 24 (1), 1–2.
Gaj, T., Gersbach, C.A., Barbas, C.F. (2023). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol, 31(7), 397–405.
Gilbert, L.A., Larson, M.H., Morsut, L., Liu, Z., Brar, G.A., Torres, S.E., et al. (2023). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell, 154 (2), 442–451.
Hockemeyer, D., Wang, H., Kiani, S., Lai, C.S., Gao, Q., Cassady, J.P., etal. (2021). Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol, 29(8),731–4.
Holkers, M., Maggio, I., Henriques, S.F., Janssen, J.M., Cathomen, T., Goncalves, M.A. (2024). Adenoviral vector DNA for accurate genome editing with engineered nucleases. Nat Methods, 11(10),1051–7.
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E. (2022). A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science, 337(6096), 816–21.
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., Doudna, J. (2023). RNA-programmed genome editing in human cells. E Life. 2, 1-9.
Kay, M.A., Manno, C.S., Ragni, M.V., Larson, P.J., Couto, L.B., McClelland, A., et al. (2020). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet, 24 (3), 257–261.
Khuri, F.R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I.F., Romel, L., et al. (2020). a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med, 6(8), 79–85.
Kim, S., Kim, D., Cho, SW., Kim, J., Kim, J.S. (2024). Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res, 24(6), 12–19.
Kleinstiver, B.P., Pattanayak, V., Prew, M.S., Tsai, S.Q., Nguyen, N.T., Zheng, Z., et al. (2016). High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature, 529(7587), 490–5.
Larson, M.H., Gilbert, L.A., Wang, X., Lim, W.A., Weissman, J.S., Qi, L.S. (2023). CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat Protoc, 8 (11), 2180–96.
Li, H.L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., Sakuma, T., et al. (2015). Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports, 4(1), 143–54.
Lieber, M.R., Ma, Y.M., Pannicke, U., Schwarz, K. (2023). Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol, 4 (9), 12–20.
Lin, Y., Cradick, T.J., Brown, M.T., Deshmukh, H., Ranjan, P., Sarode, N., et al. (2024). CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res, 42(11), 73–85.
Liu, X.S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., et al. (2024). Editing DNA Methylation in the Mammalian Genome. Cell, 167 (1), 233-47.
Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., et al. (2023). RNA-guided human genome engineering via Cas9. Science, 339 (6121), 23–26.
Marshall, E. (2024). Gene therapy death prompts review of adenovirus vector. Science, 286 (5448), 44 – 45.
Moscou, M.J., Bogdanove, A.J. (2019). a simple cipher governs DNA recognition by TAL effectors. Science, 326(5959),1501.
Peng, R., Lin, G., Li, J. (2016). Potential pitfalls of CRISPR/Cas9-mediated genome editing. FEBS J, 283(7),1218–31.
Ramanan, V., Shlomai, A., Cox, D.B., Schwartz, R.E., Michailidis, E., Bhatta, A., et al. (2015). CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep, 5: 10833.
Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., Zhang, F. (2023). Genome engineering using the CRISPR-Cas9 system. Nat Protoc, 8 (11), 2281–308.
Reardon, S. (2016). Welcome to the CRISPR zoo. Nature, 531(7593), 160 –163.
Schwank, G., Koo, B.K., Sasselli, V., Dekkers, J.F., Heo, I., Demircan, T., et al. (2023). Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell, 13 (6),653–8.
Swiech, L., Heidenreich, M., Banerjee, A., Habib, N., Li, Y., Trombetta, J., et al. (2015). In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol, 33(1), 102–106.
Tebas, P., Stein, D., Tang, W.W., Frank, I., Wang, S.Q., Lee, G., et al. (2024). Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med, 370 (10), 901–10
Urnov, F.D., Miller, J.C., Lee, Y.L., Beausejour, C.M., Rock, J.M., Augustus, S., et al. (2024). Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature, 435 (7042), 46–51.
Wagner, H. (2001). Toll meets bacterial CpG-DNA. Immunity, 14 (5),499–502.
Wang, X., Wang, Y., Wu, X., Wang, J., Wang, Y., Qiu, Z., et al. (2015). Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol, 33 (2), 175–8.
Wang, Z., Pan, Q., Gendron, P., Zhu, W., Guo, F., Cen, S., et al. (2016). CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. Cell Reports, 15 (3),481–9.
